Mechanisms driving the immunoregulatory function of cancer cells
The DOI matches its Crossref record; 311 of the 311 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–311 of 311
Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
Li, J., Wang, W., Zhang, Y., Cieślik, M., Guo, J., Tan, M., Green, M. D., Wang, W., Lin, H., Li, W., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134402 · Cited by 191
Falahat, R., Berglund, A., Putney, R. M., Perez-Villarroel, P., Aoyama, S., Pilon-Thomas, S., Barber, G. N., & Mulé, J. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013598118 · Cited by 190
Communication in the Cancer Microenvironment as a Target for Therapeutic Interventions
Dominiak, A., Chełstowska, B., Olejarz, W., & Nowicka, G. (2020) · Cancers · doi:10.3390/cancers12051232 · Cited by 188
Hendrickx, W., Simeone, I., Anjum, S., Mokrab, Y., Bertucci, F., Finetti, P., Curigliano, G., Seliger, B., Cerulo, L., Tomei, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1253654 · Cited by 185
Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy
Knudsen, E. S., Pruitt, S. C., Hershberger, P. A., Witkiewicz, A. K., & Goodrich, D. W. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.03.005 · Cited by 185
Muthalagu, N., Monteverde, T., Raffo-Iraolagoitia, X., Wiesheu, R., Whyte, D., Hedley, A., Laing, S., Kruspig, B., Upstill-Goddard, R., Shaw, R., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0620 · Cited by 182
Barroso-Sousa, R., Keenan, T. E., Pernas, S., Exman, P., Jain, E., Garrido-Castro, A. C., Hughes, M., Bychkovsky, B., Umeton, R., Files, J. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3507 · Cited by 182
Endogenous Myc maintains the tumor microenvironment
Sodir, N. M., Swigart, L. B., Karnezis, A. N., Hanahan, D., Evan, G. I., & Soucek, L. (2011) · Genes & Development · doi:10.1101/gad.2038411 · Cited by 179
Germline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses
Blagih, J., Zani, F., Chakravarty, P., Hennequart, M., Pilley, S., Hobor, S., Hock, A. K., Walton, J. B., Morton, J. P., Gronroos, E., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.028 · Cited by 173
Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms
Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J., Lunardi, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4463 · Cited by 172
Zimmerli, D., Brambillasca, C. S., Talens, F., Bhin, J., Linstra, R., Romanens, L., Bhattacharya, A., Joosten, S. E. P., Silva, A. M. D., Padrão, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34000-6 · Cited by 172
Tissue-resident macrophages: guardians of organ homeostasis
Nobs, S. P., & Kopf, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.04.007 · Cited by 170
Immune Response Regulation in the Tumor Microenvironment by Hypoxia
Labiano, S., Palazón, A., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.009 · Cited by 169
A single-cell tumor immune atlas for precision oncology
Nieto, P., Elosua-Bayes, M., Trincado, J. L., Marchese, D., Massoni-Badosa, R., Salvany, M., Henriques, A., Nieto, J., Aguilar-Fernández, S., Mereu, E., et al. (2021) · Genome Research · doi:10.1101/gr.273300.120 · Cited by 169
Moo-Young, T. A., Larson, J. W., Belt, B. A., Tan, M. C., Hawkins, W. G., Eberlein, T. J., Goedegebuure, P. S., & Linehan, D. C. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318189f13c · Cited by 165
Wislez, M., Fujimoto, N., Izzo, J. G., Hanna, A. E., Cody, D. D., Langley, R. R., Tang, H., Burdick, M. D., Sato, M., Minna, J. D., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3842 · Cited by 164
McDowell, S. A. C., Luo, R. B. E., Arabzadeh, A., Doré, S., Bennett, N. C., Breton, V., Karimi, E., Rezanejad, M., Yang, R. R., Lach, K. D., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00194-9 · Cited by 164
Cristescu, R., Aurora-Garg, D., Albright, A., Xu, L., Liu, X. Q., Loboda, A., Lang, L., Jin, F., Rubin, E. H., Snyder, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003091 · Cited by 164
Immune-mediated mechanisms influencing the efficacy of anticancer therapies
Coffelt, S. B., & de Visser, K. E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.006 · Cited by 163
Muñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
Bruand, M., Barras, D., Mina, M., Ghisoni, E., Morotti, M., Lanitis, E., Fahr, N., Desbuisson, M., Grimm, A. J., Zhang, H., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109412 · Cited by 158
Tumor Cell–Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Weiss, G. J., Beck, J., Braun, D. P., Bornemann-Kolatzki, K., Barilla, H., Cubello, R., Quan, W., Sangal, A., Khemka, V., Waypa, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0231 · Cited by 154
Deniger, D. C., Pasetto, A., Robbins, P. F., Gartner, J. J., Prickett, T. D., Paria, B. C., Malekzadeh, P., Jia, L., Yossef, R., Langhan, M. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0573 · Cited by 154
Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape
Takeuchi, Y., Tanegashima, T., Sato, E., Irie, T., Sai, A., Itahashi, K., Kumagai, S., Tada, Y., Togashi, Y., Koyama, S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abc6424 · Cited by 149
Glucagon Regulation of Energy Expenditure
Kleinert, M., Sachs, S., Habegger, K. M., Hofmann, S. M., & Müller, T. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215407 · Cited by 147
Tijhuis, A. E., Johnson, S. C., & McClelland, S. E. (2019) · Molecular Cytogenetics · doi:10.1186/s13039-019-0429-1 · Cited by 143
Garcia, A. J., Ruscetti, M., Arenzana, T. L., Tran, L. M., Bianci-Frias, D., Sybert, E., Priceman, S. J., Wu, L., Nelson, P. S., Smale, S. T., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.00090-14 · Cited by 142
Pakish, J. B., Zhang, Q., Chen, Z., Liang, H., Chisholm, G. B., Yuan, Y., Mok, S. C., Broaddus, R. R., Lu, K. H., & Yates, M. S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2655 · Cited by 141
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Gray, J. E., Saltos, A., Tanvetyanon, T., Haura, E. B., Creelan, B., Antonia, S. J., Shafique, M., Zheng, H., Dai, W., Saller, J. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1305 · Cited by 141
Heijink, A. M., Talens, F., Jae, L. T., van Gijn, S. E., Fehrmann, R. S. N., Brummelkamp, T. R., & van Vugt, M. A. T. M. (2019) · Nature Communications · doi:10.1038/s41467-018-07927-y · Cited by 140
From bench to bedside: Single-cell analysis for cancer immunotherapy
Davis-Marcisak, E. F., Deshpande, A. M., Stein-O’Brien, G., Ho, W. J., Laheru, D. A., Jaffee, E. M., Fertig, E. J., & Kagohara, L. T. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.004 · Cited by 136
Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis
Nishida, J., Momoi, Y., Miyakuni, K., Tamura, Y., Takahashi, K., Koinuma, D., Miyazono, K., & Ehata, S. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0491-2 · Cited by 135
Le, X., Negrao, M. V., Reuben, A., Federico, L., Diao, L., McGrail, D. J., Nilsson, M. B., Robichaux, J. P., Guijarro, I., Patel, S. A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.010 · Cited by 135
Serresi, M., Gargiulo, G., Proost, N., Siteur, B., Cesaroni, M., Koppens, M. A. J., Xie, H., Sutherland, K. D., Hulsman, D., Citterio, E., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.006 · Cited by 131
Wang, G., Xu, D., Zhang, Z., Li, X., Shi, J., Sun, J., Li, X., Li, X., Zhou, M., & Zheng, T. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00200-4 · Cited by 131
Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01846-x · Cited by 129
The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Germano, G., Amirouchene-Angelozzi, N., Rospo, G., & Bardelli, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0150 · Cited by 128
de la Iglesia, J. V., Slebos, R. J. C., Martin‐Gomez, L., Wang, X., Teer, J. K., Tan, A. C., Gerke, T. A., Aden-Buie, G., van Veen, T., Masannat, J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1769 · Cited by 127
Dushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00728-9 · Cited by 124
HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway
Herrmann, F., Lehr, H.-A., Drexler, I., Sutter, G., Hengstler, J., Wollscheid, U., & Seliger, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2522-2 · Cited by 123
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 123
Saleh, R., Toor, S. M., Nair, V. S., & Elkord, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01469 · Cited by 121
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
Bouillez, A., Rajabi, H., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 120
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119
Wasserman, I., Lee, L. H., Ogino, S., Marco, M. R., Wu, C., Chen, X., Datta, J., Sadot, E., Szeglin, B. C., Guillem, J. G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1726 · Cited by 119
Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
Malekzadeh, P., Yossef, R., Cafri, G., Paria, B. C., Lowery, F. J., Jafferji, M., Good, M. L., Sachs, A., Copeland, A. R., Kim, S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1874 · Cited by 118
Ladoire, S., Enot, D., Senovilla, L., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Semeraro, M., Chaix, M., Penault-Llorca, F., Arnould, L., et al. (2016) · Autophagy · doi:10.1080/15548627.2016.1154244 · Cited by 117
Autophagy Induced by Conventional Chemotherapy Mediates Tumor Cell Sensitivity to Immunotherapy
Ramakrishnan, R., Huang, C., Cho, H.-I., Lloyd, M. C., Johnson, J., Ren, X., Altiok, S., Sullivan, D. M., Weber, J. S., Celis, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2236 · Cited by 116
PTEN functions as a melanoma tumor suppressor by promoting host immune response
Dong, Y., Richards, J.-A., Gupta, R., Aung, P. P., Emley, A., Kluger, Y., Dogra, S. K., Mahalingam, M., & Wajapeyee, N. (2014) · Oncogene · doi:10.1038/onc.2013.409 · Cited by 113
HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy
Triulzi, T., Forte, L., Regondi, V., Modica, M. D., Ghirelli, C., Carcangiu, M. L., Sfondrini, L., Balsari, A., & Tagliabue, E. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512942 · Cited by 113
Chida, K., Kawazoe, A., Kawazu, M., Suzuki, T., Nakamura, Y., Nakatsura, T., Kuwata, T., Ueno, T., Kuboki, Y., Kotani, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0401 · Cited by 110
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
Miller, L. D., Chou, J., Black, M. A., Print, C. G., Chifman, J., Alistar, A. T., Putti, T. C., Zhou, X., Bedognetti, D., Hendrickx, W., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0149 · Cited by 108
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
Roelands, J. P., Hendrickx, W., Zoppoli, G. M., Mall, R., Saad, M., Halliwill, K. D., Curigliano, G., Rinchai, D., Decock, J. V., Delogu, L. G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000617 · Cited by 108
PTEN loss correlates with T cell exclusion across human cancers
Lin, Z., Huang, L., Li, S. L., Gu, J., Cui, X., & Zhou, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08114-x · Cited by 106
Ly6E/K Signaling to TGFβ Promotes Breast Cancer Progression, Immune Escape, and Drug Resistance
AlHossiny, M., Luo, L., Frazier, W. R., Steiner, N., Gusev, Y., Kallakury, B., Glasgow, E., Creswell, K., Madhavan, S., Kumar, R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2654 · Cited by 104
Pingili, A. K., Chaib, M., Sipe, L. M., Miller, E. J., Teng, B., Sharma, R., Yarbro, J. R., Asemota, S., Abdallah, Q. A., Mims, T. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109285 · Cited by 104
Li, H., Liu, Z., Liu, L., Zhang, H., Han, C., Girard, L., Park, H., Zhang, A., Dong, C., Ye, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100554 · Cited by 102
Gomez‐Aleza, C., Nguyen, B., Yoldi, G., Ciscar, M., Barranco, A., Hernández-Jiménez, E., Maetens, M., Salgado, R., Zafeiroglou, M., Pellegrini, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20138-8 · Cited by 100
Zhou, Y., Bastian, I. N., Long, M. D., Dow, M., Li, W., Liu, T., Ngu, R. K., Antonucci, L., Huang, J. Y., Phung, Q. T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025840118 · Cited by 100
Sunaga, N., Imai, H., Shimizu, K., Shames, D. S., Kakegawa, S., Girard, L., Sato, M., Kaira, K., Ishizuka, T., Gazdar, A. F., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26164 · Cited by 99
Fan, P., Zhao, J., Meng, Z., Wu, H., Wang, B., Wu, H., & Jin, X. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1044-z · Cited by 99
Alghamri, M. S., McClellan, B. L., Avvari, R., Thalla, R., Carney, S. V., Hartlage, C. S., Haase, S., Ventosa, M., Taher, A. W., Kamran, N., et al. (2021) · Science Advances · doi:10.1126/sciadv.abh3243 · Cited by 98
PD-L1 (CD274) promoter methylation predicts survival in colorectal cancer patients
Goltz, D., Gevensleben, H., Dietrich, J., & Dietrich, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1257454 · Cited by 96
Pao, W., Ooi, C.-H., Birzele, F., Ruefli-Brasse, A., Cannarile, M. A., Reis, B., Scharf, S. H., Schubert, D. A., Hatje, K., Pelletier, N., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1320 · Cited by 96
Cell Programmed Nutrient Partitioning in the Tumor MicroenvironmentPreprint
Reinfeld, B. I., Madden, M. Z., Wolf, M., Chytil, A. M., Bader, J. E., Patterson, A. R., Cohen, A., Ali, A. K., Do, B. T., Muir, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.10.238428 · Cited by 96
The long journey to bring a Myc inhibitor to the clinic
Whitfield, J. R., & Soucek, L. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202103090 · Cited by 96
An, Y., Wu, Z., Wang, N., Yang, Z., Li, Y., Xu, B., & Sun, M. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02404-x · Cited by 90
Du, F., Qi, X., Zhang, A., Sui, F., Wang, X., Proud, C. G., Lin, C., Fan, X., & Li, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00670-3 · Cited by 87
Zhou, J. X., Taramelli, R., Pedrini, E., Knijnenburg, T., & Huang, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-09307-w · Cited by 85
Gevensleben, H., Holmes, E. E., Goltz, D., Dietrich, J., Sailer, V., Ellinger, J., Dietrich, D., & Kristiansen, G. (2016) · Oncotarget · doi:10.18632/oncotarget.13161 · Cited by 84
Evaluating the impact of age on immune checkpoint therapy biomarkers
Erbe, R., Wang, Z., Wu, S. K., Xiu, J., Zaidi, N., La, J., Tuck, D. P., Fillmore, N. R., Giraldo, N. A., Topper, M. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109599 · Cited by 84
Cheng, H., Fan, K., Luo, G., Fan, Z., Yang, C., Huang, Q., Jin, K., Xu, J., Yu, X., & Liu, C. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.013 · Cited by 83
Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression
van den Bulk, J., de Miranda, N. F. C. C., & ten Dijke, P. (2021) · Clinical Science · doi:10.1042/cs20201236 · Cited by 82
Siolas, D., Vucic, E., Kurz, E., Hajdu, C., & Bar-Sagi, D. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109578 · Cited by 80
Zhu, S., Ma, A.-H., Zhu, Z. G., Adib, E., Rao, T., Li, N., Ni, K., Chittepu, V. C. S. R., PRABHALA, R. H., Risco, J. G., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002917 · Cited by 80
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
Kato, S., Weng, Q. Y., Insco, M. L., Chen, K. Y., Muralidhar, S., Poźniak, J., Diaz, J. M. S., Drier, Y., Nguyen, N. T., Lo, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0532 · Cited by 79
The Role of CXC Chemokines in Cardiovascular Diseases
Lu, X., Wang, Z., Ye, D., Feng, Y., Liu, M., Xu, Y. Q., Wang, M., Zhang, J., Liu, J., Zhao, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.765768 · Cited by 78
Tian, H., Sparvero, L. J., Anthonymuthu, T. S., Sun, W., Amoscato, A. A., He, R., Bayır, H., Kagan, V. E., & Winograd, N. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.0c05311 · Cited by 74
Okita, R., Mougiakakos, D., Ando, T., Mao, Y., Sarhan, D., Wennerberg, E., Seliger, B., Lundqvist, A., Mimura, K., & Kiessling, R. W. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102237 · Cited by 73
Novel targets and interaction partners of mutant p53 Gain-Of-Function
Aschauer, L., & Muller, P. A. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150261 · Cited by 72
Triner, D., Xue, X., Schwartz, A. J., Jung, I., Colacino, J. A., & Shah, Y. M. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00481-16 · Cited by 72
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers
van Vugt, M. A. T. M., & Parkes, E. E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2021.12.003 · Cited by 67
The multifaceted role of autophagy in tumor evasion from immune surveillance
Janji, B., Viry, E., Moussay, E., Paggetti, J., Arakelian, T., Mgrditchian, T., Messai, Y., Noman, M. Z., Moer, K. V., Hasmim, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7540 · Cited by 65
Manzano, R. G., Catalán-Latorre, A., & Brugarolas, A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08078-y · Cited by 61
Ni, Y., Soliman, A., Joehlin-Price, A., Rose, P. G., Vlad, A., Edwards, R. P., & Mahdi, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00242-8 · Cited by 55
Tittarelli, A., Mendoza‐Naranjo, A., Vergara, M. F., Guerrero, I., Ihara, F., Wennerberg, E., Riquelme, S. A., Gleisner, M. A., Kalergis, A. M., Lundqvist, A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301297 · Cited by 54
IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice
Richardson, L. G., Nieman, L. T., Stemmer-Rachamimov, A. O., Zheng, X. S., Stafford, K., Nagashima, H., Miller, J. J., Kiyokawa, J., Ting, D. T., Wakimoto, H., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1806662 · Cited by 53
Mutant p53 in cell-cell interactions
Pilley, S., Rodriguez, T. A., & Vousden, K. H. (2021) · Genes & Development · doi:10.1101/gad.347542.120 · Cited by 53
Garrido, P., Pujol, J.-L., Kim, E. S., Lee, J. M., Tsuboi, M., Gómez‐Rueda, A., Benito, A., Moreno‐Mata, N., Gorospe, L., Dong, T., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1098 · Cited by 52
Kim, S., Ramakrishnan, R., Lavilla-Alonso, S., Chinnaiyan, P., Rao, N. G., Fowler, E. E. E., Heine, J., & Gabrilovich, D. I. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1573-4 · Cited by 50
Chen, B., Li, L., Li, M., & Wang, X. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00534-4 · Cited by 46
Hierarchical cortical networks of “voice patches” for processing voices in human brain
Zhang, Y., Ding, Y., Huang, J., Zhou, W., Ling, Z., Hong, B., & Wang, X. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113887118 · Cited by 46
Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma
Maruyama, T., Mimura, K., Sato, E., Watanabe, M., Mizukami, Y., Kawaguchi, Y., Ando, T., Kinouchi, H., Fujii, H., & Kono, K. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605772 · Cited by 45
Meyer, M., Wang, Y., Edwards, D. K., Smith, G. R., Rubenstein, A. B., Ramanathan, P., Mire, C. E., Pietzsch, C. A., Chen, X., Ge, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148036 · Cited by 43
Hofmann-Vega, F., Navarrete, M., Álvarez, J., Guerrero, I., Gleisner, M. A., Tittarelli, A., & Salazar‐Onfray, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184509 · Cited by 38
Acetylation in Tumor Immune Evasion Regulation
Lu, J., He, X., Zhang, L., Zhang, R., & Li, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.771588 · Cited by 31
A Single-Cell Tumor Immune Atlas for Precision Oncology
Nieto, P., Elosua-Bayes, M., Trincado, J. L., Marchese, D., Massoni-Badosa, R., Salvany, M., Henriques, A., Mereu, E., Moutinho, C., Ruiz, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.26.354829 · Cited by 30
Shui, I. M., Liu, X. Q., Zhao, Q., Kim, S. T., Sun, Y. M., Yearley, J. H., Choudhury, T., Webber, A. L., Krepler, C., Cristescu, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004879 · Cited by 30
Implications of IDH mutations on immunotherapeutic strategies for malignant glioma
Richardson, L. G., Miller, J. J., Kitagawa, Y., Wakimoto, H., Choi, B. D., & Curry, W. T. (2022) · Neurosurgical FOCUS · doi:10.3171/2021.11.focus21604 · Cited by 28
Knab, V. M., Gotthardt, D., Klein, K., Grausenburger, R., Heller, G., Menzl, I., Prinz, D., Trifinopoulos, J., List, J., Fux, D. A., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04279-2 · Cited by 27
Ma, Y., Liu, N., Wang, Y., Zeng, J., Hu, Y., Wu, H., Shi, H., Zhu, P., Lv, J., Fan, W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003712 · Cited by 27
CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver
Kaltenbacher, T., Löprich, J., Maresch, R., Weber, J., Müller, S., Oellinger, R., Groß, N., Griger, J., Krätzig, N. D. A., Avramopoulos, P., et al. (2022) · Nature Protocols · doi:10.1038/s41596-021-00677-0 · Cited by 26
Lima, A., & Maddalo, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.667189 · Cited by 25
Local immune response depends on p16INK4a status of primary tumor in vulvar squamous cell carcinoma
Sznurkowski, J. J., Żawrocki, A., & Biernat, W. (2017) · Oncotarget · doi:10.18632/oncotarget.17581 · Cited by 24
Mehta, A. K., Cheney, E. M., Hartl, C., Pantelidou, C., Oliwa, M., Castrillon, J. A., Lin, J., Hurst, K. E., Taveira, M. D. O., Johnson, N. T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-sitc2020.0860 · Cited by 24
The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice
van der Weyden, L., Jonkers, J., & Adams, D. J. (2021) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2020.12.005 · Cited by 24
RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status
Sinha, A., Saleh, A. J., Endersby, R., Yuan, S. H., Chokshi, C., Brown, K. R., Kuzio, B., Kauppinen, T. M., Singh, S. K., Baker, S. J., et al. (2020) · Cancers · doi:10.3390/cancers12113178 · Cited by 21
Evaluating the impact of age on immune checkpoint therapy biomarkers
Erbe, R., Wang, Z., Wu, S. K., Xiu, J., Zaidi, N., La, J., Tuck, D. P., Fillmore, N. R., Giraldo, N. A., Topper, M. J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110033 · Cited by 19
Cooks, T., Pateras, I., Tarcic, O., Solomon, H., Schetter, A., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rozenfeld, N., et al. (2013) · UCL Discovery (University College London) · Cited by 12
The Role of the JAK/STAT Signalling Pathway in Immunoregulation of Gastrointestinal Cancers
Vaddi, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-43063-8_7 · Cited by 3
Cited by
Breast cancer: pathogenesis and treatments
Xiong, X., Zheng, L.-W., Ding, Y., Chen, Y.-F., Cai, Y.-W., Wang, L.-P., Huang, L., Liu, C.-C., Shao, Z.-M., & Yu, K.-D. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02108-4 · Cited by 958
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Metadata
- Authors
- van Weverwijk, A., & de Visser, K. E.
- Venue
- Nature Reviews Cancer
- Published
- 2023-01-30
- Volume
- 23
- Issue
- 4
- Pages
- 193-215
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W4318483748
- Cited by
- 272
- References
- 311
- FWCI
- 13.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.